OLOrnella Ludovico

Ornella Ludovico

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ornella Ludovico has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Antonio Minenna

    Unit of Endocrinology, Scientific Institute “Casa Sollievo della Sofferenza,” S. Giovanni Rotondo, Italy

    1 shared publication
  • Fabio Pellegrini

    Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy

    1 shared publication
  • Francesco Andreozzi

    Department of Medical and Surgical Sciences, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, Italy

    1 shared publication
  • Giorgio Sesti

    Department of Clinical and Molecular Medicine, University of Rome-Sapienza, 00189 Rome, Italy

    1 shared publication
  • Maria Adelaide Marini

    Department of Internal Medicine, University of “Tor Vergata,” Rome, Italy

    1 shared publication
  • Marina Cardellini

    Department of Internal Medicine, University of “Tor Vergata,” Rome, Italy

    1 shared publication

Latest Publications

  • Open Access

    Heterogeneous Effect of Peroxisome Proliferator‐activated Receptor γ2 Ala12 Variant on Type 2 Diabetes Risk

    by Ornella Ludovico, Fabio Pellegrini, Rosa Di Paola, Antonio Minenna, Sandra Mastroianno, Marina Cardellini, Maria Adelaide Marini, Francesco Andreozzi, Olga Vaccaro, Giorgio Sesti, et al.

    Conflicting results have been reported regarding whether the PPARγ2 Pro12Ala polymorphism plays a role in the risk of type 2 diabetes (T2D), suggesting genetic heterogeneity. To investigate this issue, a meta‐analysis of 41 published and 2 unpublished studies (a total of 42,910 subjects) was conducted. Ala12 carriers had a 19% T2D risk reduction, but this association was highly heterogeneous (p = 0.005). A great proportion (48%) of heterogeneity was explained by the controls’ BMI, with risk reduction being greater when BMI was lower. Risk reduction of Ala12 carriers in Asia (35%) was higher than in Europe (15%, p = 0.02) and tended to be higher than in North America (18%, p = 0.10). Difference between Asians and Europeans was no longer significant (p = 0.15) after adjusting for the controls’ BMI. Studies from Europe were still heterogeneous (p = 0.02) with risk reduction in Ala12 carriers being progressively smaller (test for trend in the odds ratios, p = 0.02) from Northern (26% reduction, p < 0.0001) to Central (10%, p = 0.04) and Southern (0%, p = 0.94) Europe. In conclusion, in our meta‐analysis, the reduced risk of T2D in Ala12 carriers is not homogeneous. It is greater in Asia than in Europe and, among Europeans, it is higher in Northern Europe, barely significant in Central Europe, and nonexistent in Southern Europe.